Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35

被引:20
作者
Kerokoski, P
Suuronen, T
Salminen, A
Soininen, H
Pirttilä, T
机构
[1] Univ Kuopio, Dept Neurosci & Neurol, FIN-70211 Kuopio, Finland
[2] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland
来源
MOLECULAR BRAIN RESEARCH | 2002年 / 106卷 / 1-2期
基金
芬兰科学院;
关键词
proteasome; calpain; Alzheimer's disease; okadaic acid; glutamate;
D O I
10.1016/S0169-328X(02)00409-6
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cyclin-dependent kinase 5 (cdk5) is involved in the development of the nervous system and neuronal process outgrowth, and it regulates several intracellular processes including cytoskeletal dynamics. Dysregulation of cdk5 has been implicated in many disorders of the nervous system. The activity of the kinase is regulated by binding of cdk5 activators (p35, p39, p67). We examined the phosphorylation of p35, and the role of phosphorylation in regulating the proteolysis of the p35 protein. By detecting changes in electrophoretic mobility, we observed that a significant proportion of p35 is phosphorylated in rat brain tissue. In cultured neurons, the phosphorylation was prevented by roscovitine, an inhibitor of cdk5 and some other cdks. The phosphatase inhibitor okadaic acid induced p35 degradation in neuronal cultures which was sensitive to the proteasome inhibitor lactacystin. These latter results agree with some previous studies showing that phosphorylation regulates proteasomal degradation of p35. Treatment of brain homogenate with okadaic acid in the presence of ATP led to accumulation of p35 phosphorylated also by a kinase that was not inhibited by roscovitine. This implies that the effect of okadaic acid on p35 degradation could also be contributed by a non-cdk kinase. The calpain protease has been shown to cleave p35. Our results suggest that this process may also be modulated by p35 phosphorylation under some conditions. We conclude that p35 phosphorylation influences the proteasome-mediated degradation of p35 and calpain-mediated cleavage of p35 to p25. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:50 / 56
页数:7
相关论文
共 50 条
  • [31] A 24-Residue Peptide (p5), Derived from p35, the Cdk5 Neuronal Activator, Specifically Inhibits Cdk5-p25 Hyperactivity and Tau Hyperphosphorylation
    Zheng, Ya-Li
    Amin, Niranjana D.
    Hu, Ya-Fang
    Rudrabhatla, Parvathi
    Shukla, Varsha
    Kanungo, Jyotshnabala
    Kesavapany, Sashi
    Grant, Philip
    Albers, Wayne
    Pant, Harish C.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (44) : 34202 - 34212
  • [32] p35/cdk5 binds and phosphorylates β-catenin and regulates β-catenin/presenilin-1 interaction
    Kesavapany, S
    Lau, KF
    McLoughlin, DM
    Brownlees, J
    Ackerley, S
    Leigh, PN
    Shaw, CE
    Miller, CCJ
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2001, 13 (02) : 241 - 247
  • [33] TFP5, a Peptide Derived from p35, a Cdk5 Neuronal Activator, Rescues Cortical Neurons from Glucose Toxicity
    Binukumar, B. K.
    Zheng, Ya-Li
    Shukla, Varsha
    Amin, Niranjana D.
    Grant, Philip
    Pant, Harish C.
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 39 (04) : 899 - 909
  • [34] Effects of p35 Mutations Associated with Mental Retardation on the Cellular Function of p35-CDK5
    Takada, Shunsuke
    Mizuno, Keiko
    Saito, Taro
    Asada, Akiko
    Giese, Karl Peter
    Hisanaga, Shin-ichi
    PLOS ONE, 2015, 10 (10):
  • [35] Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases
    Binukumar, B. K.
    Pelech, Steven L.
    Sutter, Catherine
    Shukla, Varsha
    Amin, Niranjana D.
    Grant, Philip
    Bhaskar, Manju
    Skuntz, Suzanne
    Steiner, Joseph
    Pant, Harish C.
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 54 (02) : 525 - 533
  • [36] Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease
    Binukumar, B. K.
    Shukla, Varsha
    Amin, Niranjana D.
    Grant, Philip
    Bhaskar, M.
    Skuntz, Susan
    Steiner, Joseph
    Pant, Harish C.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26 (24) : 4478 - 4491
  • [37] A virtual screening approach for Cdk5/p35 inhibitors based on common feature pharmacophore modeling and molecular docking
    Yang, Ran-yao
    Fang, Jian-song
    Liu, Ai-lin
    Du, Guan-hua
    ACTA PHARMACOLOGICA SINICA, 2013, 34 : 47 - 47
  • [38] p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity
    Zhang, Lingyan
    Liu, Wen
    Szumlinski, Karen K.
    Lew, John
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (49) : 20041 - 20046
  • [39] Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease
    Alrouji, Mohammed
    Al-kuraishy, Haydar M.
    Al-Gareeb, Ali I.
    Alshammari, Mohammed S.
    Alexiou, Athanasios
    Papadakis, Marios
    Bahaa, Mostafa M.
    Batiha, Gaber El-Saber
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (11)
  • [40] Amyloid-β Fosters p35/CDK5 Signaling Contributing to Changes of Inhibitory Synapses in Early Stages of Cerebral Amyloidosis
    Kiss, Eva
    Groeneweg, Femke
    Gorgas, Karin
    Schlicksupp, Andrea
    Kins, Stefan
    Kirsch, Joachim
    Kuhse, Jochen
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 74 (04) : 1167 - 1187